The inhibitors intended to target metabolic enzymes, such as SLC25A1 (CPT1) [38], MCT1 (MCT-III) [39], LDHA (oxamate) [40], glutamine transporter (MK801) [41], and PDH/α-ketoglutarate (Demvistat) [42], without affecting cell viability in the lymphoma cells or LCL (see Figure S1). The gene discussed is PDP1; the disease is lymphoma.